Dysregulation of IRS-proteins causes insulin resistance and diabetes

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 1, 2000, Pages 1-7

  Aguirre, Vincent ^a   White, Morris F ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 1BETA; PROTEIN SERINE THREONINE KINASE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CARBOHYDRATE METABOLISM; CELL FUNCTION; DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; SIGNAL TRANSDUCTION;

EID: 0034050823     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200002000-00001     Document Type: Article

References (56)

1. 1 Kimura KD, Tissenbaum HA, Liu Y, Ruvkun G: daf-2, An insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans [see comments]. Science 1997, 277(5328):942-946.
2. 2 Bohni R, Riesgo-Escovar J, Oldham S, Brogiolo W, Stocker H, Andruss BF, et al: Autonomous control of cell and organ size by CHICO, a drosophila homolog of vertegrate IRS1-4. Cell 1999, 97:865-875. This paper describes the identification of a drosophila IRS-protein that promote embryonic and adult growth.
3. 3 Carter EA: Insulin resistance in burns and trauma. Nutr Rev 1998, 56(1 Pt 2):S170-S176.
4. 4 Mizock BA: Alterations in carbohydrate metabolism during stress: a review of the literature. Am J Med 1995, 98(1):75-84.
5. 5 Maezono K, Osman A, Patti ME, Cusi K, Pendergrass M, DeFronzo RA, et al.: Pl 3-kinase but not map kinase signaling is insulin resistant in obesity and niddm. Diabetes 47 [Supp 1], A333. 1998.
6. 6 DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997, 5(3):177-269.
7. 7 Tsuiki S, Suzuki Y, Tamura S, Kikuchi K: Liver phosphotyrosine protein phosphatase and tyrosine protein kinase in chemical hepatocarcinogenesis [in Japanese]. Gan To Kagaku Ryoho 1987, 14:2010-2017.
8. 8 Hani EH, Suaud L, Boutin P, Chevre JC, Durand E, Philippi A, et al.: A missense mutation in hepatocyte nuclear factor-4 alpha, resulting in a reduced transactivation activity, in human late-onset non-insulin-dependent diabetes mellitus [In Process Citation]. J Clin Invest 1998, 101(3):521-526.
9. 9 Carboni JM, Yan N, Cox AD, Bustelo X, Graham SM, Lynch MJ, et al.: Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation. Oncogene 1995, 10(10):1905-1913.
10. 10 Vaxillaire M, Rouard M, Yamagata K, Oda N, Kaisaki PJ, Boriraj VV, et al.: Identification of nine novel mutations in the hepatocyte nuclear factor 1 alpha gene associated with maturity-onset diabetes of the young (MODY3). Hum Mol Genet 1997, 6(4):583-586.
11. 11 Comb DG, Roseman S: Glucosamine metabolism. IV. Glucosamine-6-phosphate deaminase. J Biol Chem 1958, 232:807-827.
12. 12 Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF: Irs-2 coordinates Igf-1 receptor-mediated b-cell development and peripheral insulin signalling. Nat Genet 1999, 23(1):32-40. This paper describes mice with combined defects in IRS-1 and IRS-2, or IGF1 receptors and IRS-2.
13. -1-mice.
14. 14 Yenush L, White MF: The IRS-signaling system during insulin and cytokine action. Bio Essays 1997, 19(5):491-500.
15. 15 Liu SC, Wang Q, Lienhard GE, Keller SR: Insulin receptor substrate 3 is not essential for growth or glucose homeostasis. J Biol Chem 1999, 274(25):18093-18099.
16. 16 Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, et al.: Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998, 391(6670):900-904. This paper was the first demonstration that IRS-2 plays a role in both peripheral insulin action and β-cell insulin secretion.
17. 17 Cobb MH, Boulton TG, Robbins DJ: Extracellular signal-regulated kinases: ERKs in progress. Cell Regulation 1991, 2:965-978.
18. 18 Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD: Phosphoinositide 3-kinases: a conserved family of signal transducers. TIBS 1997, 22:267-272.
19. 19 Alessi DR, Cohen P: Mechanism of activation and function of protein kinase B. Curr Opin Gene 1998, 8(1):55-62.
20. 20 Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al.: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor [In Process Citation]. Cell 1999, 96(6):857-868.
21. 21 Araki E, Lipes MA, Patti ME, Brüning JC, Haag BL, III, Johnson RS, et al.: Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994, 372(6502):186-190.
22. 22 Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, et al.: Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994, 372(6502):182-186.
23. 23 Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR: Tissue-specific knockout of the insulin receptor in pancreatic b cells creates an insulin secretory defect similar to that in Type 2 diabetes. Cell 1999, 96(3):329-339.
24. 24 Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, et al.: A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998, 2(5):559-569.
25. 25 Patti ME, Sun XJ, Bruning JC, Araki E, Lipes MA, White MF, et al.: 4PS/IRS-2 is the alternative substrate of the insulin receptor in IRS-1 deficient mice. J Biol Chem 1995, 270(42):24670-24673.
26. 26 Yamauchi T, Tobe K, Tamemoto H, Ueki K, Kaburagi Y, Yamamoto-Handa R, et al.: Insulin signaling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol 1996, 16(6):3074-3084.
27. 27 Higaki Y, Wojtaszewski JF, Hirshman MF, Withers DJ, Towery H, White MF, et al.: Insulin receptor substrate-2 is not necessary for insulin-and exercise-stimulated glucose transport in skeletal muscle. J Biol Chem 1999, 274(30):20791-20795.
28. 28 Virkamaki A, Ueki K, Kahn CR: Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999, 103(7):931-943.
29. 29 Kido Y, Burks DJ, Withers DJ, Bruning JC, Kahn CR, White MF, et al.: Tissue-specific patterns of insulin resistance in mice with combined mutations of insulin receptor and its main substrates IRS-1 and IRS-2. J Clin Invest In press. This paper compared the effect of compound heterozygous disruption of the insulin receptor, together with IRS-1, IRS-2, or both.
30. 30 Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993, 75:73-82.
31. 31 Liu JP, Baker J, Perkins JA, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75:59-72.
32. 32 Taylor SI, Cama A, Accili D, Barbetti F, Quon MJ, de la Luz Sierra M, et al.: Mutations in the insulin receptor gene. Endocr Rev 1992, 3:566-595.
33. 33 Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald SM, Pedersen O: Amino acid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 1993, 342(8875):828-832.
34. 34 Almind K, Inoue G, Pedersen O, Kahn CR: A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996, 97(11):2569-2575.
35. 35 Porzio O, Federici M, Hribal ML, Lauro D, Accili D, Lauro R, et al.: The Gly972 to Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic b cells. J Clin Invest 1999, 104:357-364.
36. 36 Bernal D, Almind K, Yenush L, Ayoub M, Zhang Y, Rosshani L, et al.: IRS-2 Amino acid polymorphisms are not associated with random type 2 diabetes among Caucasians. Diabetes 1998, 47:976-979.
37. 37 Sun XJ, Goldberg JL, Qiao LY, Mitchell JJ: Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. Diabetes 1999, 48(7):1359-1364.
38. 38 Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, et al.: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene [see comments]. Science 1999, 283(5407):1544-1548. The effect of PTP1B disruption on insulin sensitivity is described in this paper: serum glucose levels are slightly low in spite of a 50% reduction in circulating insulin levels. Unlike normal mice, mice lacking PTP1B do not gain weight and do no develop insulin resistance while eating a high-fat diet.
39. 39 Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al.: Effects of free fatty acids on glucose transport and IRS-1-assoiated phosphatidylinositol 3-kinase activity. J Clin Invest 1999, 103(2):253-259.
40. 40 De Fea K, Roth RA: Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 1997, 272(50):31400-31406.
41. 41 Myers MG Jr, Mendez R, Shi P, Pierce JH, Rhoads R, White MF: The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling [In Process Citation]. J Biol Chem 1998, 273(41):26908-26914.
42. 42 Goldstein BJ, Bittner-Kowalcyk A, White MF, Harbeck M: Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein tyrosine phosphatase 1B: possible facilitation by the formation of a ternary complex with the Grb-2 adaptor protein. J Biol Chem In press.
43. 43 Mothe I, Van Obberghen E: Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 662, and 731 modulates insulin action. J Biol Chem 1996, 271 (19):11222-11227.
44. 44 Tanti JF, Gremeaux T, Van Obberghen E, Le Marchand-Brustel Y: Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 1994, 269(8):6051-6057.
45. 45 Hotamisligil GS, Peraldi P, Budvari A, Ellis RW, White MF, Spiegelman BM: IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science 1996, 271 (5249):665-668.
46. 46 Loddick SA, Rothwell NJ: Mechanisms of tumor necrosis factor alpha action on neurodegeneration: interaction with insulin-like growth factor-1. Proc Natl Acad Sci U S A 1999, 96(17):9449-9451.
47. 47 Hotamisligil GS, Spiegelman BM: Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994, 43(11):1271-1278.
48. 48 Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
49. 49 Hotamisligil GS: The role of TNFa and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245(6):621-625. A review summarizing the role of TNFα receptor signaling during insulin resistance.
50. 50 Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997, 389:610-614.
51. 51 Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996, 334(26):1717-1725.
52. 52 Hyslop PA, Kuhn CE, Sauerheber RD: Insulin stimulation of adipocyte membrane glucose transport: a graded biologic response insensitive to bilayer tipid disordering. Biochem Biophys Res Commun 1987, 36:2305-2310.
53. 53 Ip YT, Davis RJ: Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol 1998, 10(2):205-219.
54. 54 Yuasa T, Ohno S, Kehrl JH, Kyriakis JM: Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase kinase kinase upstream of MKK6 and p38. J Biol Chem 1998, 273(35):22681-22692.
55. 307. J Biol Chem In press.
56. 56 Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, et al.: Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999, 341:240-246.